Itraconazole

CHEMBL64391 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
705.6 g/mol
LogP
5.7
Phase
4

This broad-spectrum triazole antifungal is used to treat various fungal infections including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. It works by inhibiting ergosterol synthesis, an essential component of the fungal cell membrane. It has many drug interactions due to its inhibition of liver cytochrome P450 enzymes.

Molecular Weight

705.6000 g/mol

LogP

5.70

TPSA

101.00 Ų

Lipinski RO5

Fail

Therapeutic Areas

Mechanism of Action

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O

InChI

InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3

Molecular Formula

C35H38Cl2N8O4

HBD / HBA

- / 9

Rotatable Bonds

11

Heavy Atoms

49

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This broad-spectrum triazole antifungal is used to treat various fungal infections including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. It works by inhibiting ergosterol synthesis, an essential component of the fungal cell membrane. It has many drug interactions due to its inhibition of liver cytochrome P450 enzymes.

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

Yes, Itraconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL64391. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 55283. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.